Divi's Laboratories Q3 PAT up 31% at Rs470.62cr on inventory efficiencies

Divi's Laboratories had another stellar quarterly performance as it reported 21.86% growth in gross revenues for the Dec-20 quarter on consolidated basis at Rs1,701.44r

Feb 06, 2021 04:02 IST India Infoline News Service

Divi's Laboratories had another stellar quarterly performance as it reported 21.86% growth in gross revenues for the Dec-20 quarter on consolidated basis at Rs1,701.44r. During the quarter, the company managed to resume normal operations across its manufacturing facilities. Divi’s Laboratories saw good traction across all its key sub-segments of business including Active Pharma Ingredients or APIs, intermediates and nutraceutical ingredients.


For the Dec-20 quarter, the consolidated operating profits were up 39.32% at Rs623.03cr. The company has deployed cost optimization and inventory efficiency measures to improve profitability. The sharp growth in operating profits is in spite of a sharp spike in raw material expenses and additional incentives worth Rs.34 crore paid to employees for COVID work appreciation. OPM expanded from 32.03% in Dec-19 quarter to 36.62% in Dec-20 quarter.


The consolidated Profit after tax (PAT) for the Dec-20 quarter was up 31.06% at Rs470.62cr as the operational trickle-down effect helped the bottom line too. PAT margins improved from 25.72% in the Dec-19 quarter to 27.66% in the Dec-20 quarter.


Financial highlights for Dec-20 compared yoy and sequentially


Divi's Laboratories
Rs in Crore Dec-20 Dec-19 YOY Sep-20 QOQ
Total Income (Rs cr) ₹ 1,701.44 ₹ 1,396.26 21.86% ₹ 1,749.30 -2.74%
Operating Profit (Rs cr) ₹ 623.03 ₹ 447.20 39.32% ₹ 680.01 -8.38%
Net Profit (Rs cr) ₹ 470.62 ₹ 359.09 31.06% ₹ 519.59 -9.42%
Diluted EPS (Rs) ₹ 17.73 ₹ 13.53 ₹ 19.57
OPM 36.62% 32.03% 38.87%
Net Margins 27.66% 25.72% 29.70%
 

Related Story

Open Free Demat Account (Rs699)